There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Viridian Therapeutics (VRDN – Research Report), Vincerx Pharma Inc (VINC – Research Report) and Pharvaris (PHVS – Research Report) with bullish sentiments.
Viridian Therapeutics (VRDN)
In a report issued on November 14, Thomas Smith from Leerink Partners reiterated a Buy rating on Viridian Therapeutics, with a price target of $45.00. The company’s shares closed last Wednesday at $15.98.
According to TipRanks.com, Smith is a top 100 analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viridian Therapeutics with a $38.82 average price target, representing a 158.8% upside. In a report issued on October 30, LifeSci Capital also maintained a Buy rating on the stock with a $57.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Vincerx Pharma Inc (VINC)
In a report issued on November 14, Jonathan Chang from Leerink Partners reiterated a Buy rating on Vincerx Pharma Inc, with a price target of $4.00. The company’s shares closed last Wednesday at $0.78, close to its 52-week low of $0.63.
According to TipRanks.com, Chang is ranked 0 out of 5 stars with an average return of
Vincerx Pharma Inc has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
Pharvaris (PHVS)
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Pharvaris on November 14 and set a price target of $24.00. The company’s shares closed last Wednesday at $16.40.
According to TipRanks.com, Schwartz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Pharvaris is a Strong Buy with an average price target of $27.00, implying a 53.0% upside from current levels. In a report issued on November 3, JMP Securities also reiterated a Buy rating on the stock with a $24.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VRDN:
- Viridian Therapeutics price target lowered to $29 from $46 at B. Riley
- Viridian Therapeutics price target lowered to $38 from $42 at JMP Securities
- Viridian Therapeutics reports Q3 EPS ($1.09), consensus ($1.24)
- VRDN Upcoming Earnings Report: What to Expect?
- Viridian Therapeutics price target lowered to $35 from $44 at RBC Capital
